Case Reports and Literature Review on Golidocitinib for MEITL Treatment

A 2026 literature review and case report analysis covering PubMed articles from 2016 to 2024 on Monomorphic Epitheliotropic Intestinal T-cell Lymphoma (MEITL). The document, authored by Xinlong Xu, presents three case studies and discusses the potential of the JAK-1 inhibitor Golidocitinib in combination with the GDP regimen to improve patient prognosis.

Use Cases

• Analyzing prognostic factors for MEITL based on patient age and clinical presentation mentioned in the description
• Reviewing treatment efficacy evidence for JAK-1 inhibitors like Golidocitinib based on the case report findings
• Studying the association between intestinal perforation and patient outcomes based on the literature review conclusions

Strengths

• Focuses on a rare and aggressive cancer with a documented median overall survival of 7 months
• Includes a literature review spanning 8 years (2016-2024) from PubMed
• Explicitly discusses a specific treatment combination (Golidocitinib with GDP regimen) and its potential mechanism

Limitations

• Row count is unknown, which may limit suitability assessment
• Column-level documentation is absent; field semantics must be inferred after download
• The description suggests further validation of long-term effectiveness is needed

Provenance

Source

figshare, author Xinlong Xu

Collection Method

Case report compilation and literature review of PubMed-indexed articles

Time Range

Literature review covers 2016 to 2024

Freshness

Last updated 2026-03-17 13:05:52; freshness should be verified

Geography

null